+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Asthma Drugs Market (2021-2026) by Medication, Administration, Source, Organization, Application, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • ID: 5392860
  • Report
  • April 2021
  • Region: Global
  • 191 pages
  • Infogence Global Research
UP TO OFF
until Nov 30th 2021
The Global Asthma Drugs Market is Estimated to be USD 15.6 Bn in 2021 and is Expected to Reach USD 23.6 Bn by 2026, Growing at a CAGR of 8.6%

FEATURED COMPANIES

  • Aerocrine AB
  • BEXIMCO Pharmaceuticals
  • GlaxoSmithKline,
  • Mundipharma
  • PARI Medical Holding
  • Roche Holding AG
The Global Asthma Drugs Market is estimated to be USD 15.6 Bn in 2021 and is expected to reach USD 23.6 Bn by 2026, growing at a CAGR of 8.6%.



Market Dynamics

The growing incidence of asthma & other breathing syndromes is one of the significant elements increasing the market's progress. Increasing awareness among the population about the accessibility of asthma therapeutics and the growth of blend remedies for the medication of respiratory disorders is another expansion factor for the market.

Some of the other aspects that drive the market are medical sciences development, cumulative healthcare expenditures, widespread research, and upgrades in healthcare structure. Though, stringent government supervisory necessity for the approval of asthma drugs, patent termination of the drugs, and the drugs indicating side effects restrict the market growth.

Market Segmentation

The Global Asthma Drugs Market is segmented further based on Medication, Administration, Source, Organization, Application, and Geography.

By medication, the market is classified as quick-relief medications, long-term control medications, and others. Amongst all, the long-term control medications segment is estimated to hold the highest market share during the forecast period.

By Administration, the market is classified as tablets and capsules, liquids, inhalers, injections, and sprays and powders. Amongst all, the tablets and capsules segment is estimated to hold the highest market share during the forecast period.

By Source, the market is classified as environment and generic. Amongst the two, the generic segment is estimated to hold the highest market share during the forecast period.

By Organization, the market is classified as private and public. Amongst the two, the public segment is estimated to hold the highest market share during the forecast period.

By Application, the market is classified as pediatric, adult, and adolescent. Amongst all, the adults segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. OMRON Healthcare launches a wheeze detection device to pre-empt asthma attacks in kids. - 3rd December 2020.
2. Teva Pharmaceutical Industries Launches Two Digital Inhalers For Asthma Patients. - 22nd September 2020.

Company Profiles

Some of the companies covered in this report are GlaxoSmithKline, Pfizer, Vectura Group, Boehringer Ingelheim, Roche, Novartis AG, Merck & Co Inc, etc.

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?
  • The report offers a comprehensive evaluation of the Global Asthma Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains a competitive analysis using the Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.
Report Highlights:
  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aerocrine AB
  • BEXIMCO Pharmaceuticals
  • GlaxoSmithKline,
  • Mundipharma
  • PARI Medical Holding
  • Roche Holding AG
1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders

2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study

3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook

4 Market Influencers
4.1 Drivers
4.1.1 Growing Prevalence of Asthma
4.1.2 Increasing Acceptance of Asthma Drugs with Approval from FDA
4.1.3 Government Initiatives Fuels the Awareness of Asthma Drugs
4.2 Restraints
4.2.1 Expiry of Patent Drugs
4.2.2 High Penetration of Generic Drugs
4.3 Opportunities
4.3.1 Technological Advancements in the Development of Asthma Drugs
4.3.2 Introduction of Generic Drugs in Developing Regions
4.4 Challenges
4.4.1 Stringent Government Regulations for the Approval of Asthma Drugs
4.5 Trends

5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis

6 Global Asthma Drugs Market, By Medication
6.1 Introduction
6.2 Quick-Relief Medications
6.3 Long-Term Control Medications
6.4 Others

7 Global Asthma Drugs Market, By Administration
7.1 Introduction
7.2 Tablets And Capsules
7.3 Liquids
7.4 Inhalers
7.5 Injections
7.6 Sprays And Powders

8 Global Asthma Drugs Market, By Source
8.1 Introduction
8.2 Environmental
8.3 Generic

9 Global Asthma Drugs Market, By Organization
9.1 Introduction
9.2 Private
9.3 Public

10 Global Asthma Drugs Market, By Application
10.1 Introduction
10.2 Pediatric
10.3 Adults
10.4 Adolescent

11 Global Asthma Drugs Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 South America
11.3.1 Brazil
11.3.2 Argentina
11.3.3 Chile
11.3.4 Colombia
11.4 Europe
11.4.1 UK
11.4.2 France
11.4.3 Germany
11.4.4 Italy
11.4.5 Spain
11.4.6 Netherlands
11.4.7 Sweden
11.4.8 Russia
11.4.9 Rest of Europe
11.5 Asia-Pacific
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4 Indonesia
11.5.5 Malaysia
11.5.6 South Korea
11.5.7 Australia
11.5.8 Sri Lanka
11.5.9 Thailand
11.5.10 Rest of APAC
11.6 Middle-East and Africa
11.6.1 Qatar
11.6.2 Saudi Arabia
11.6.3 South Africa
11.6.4 United Arab Emirates

12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
12.3 Strategic Initiatives
12.3.1 M&A and Investments
12.3.2 Partnerships and Collaborations
12.3.3 Product Developments and Improvements

13 Company Profiles
13.1 Aerocrine AB
13.2 AMIKO Digital Health
13.3 AstraZeneca
13.4 BEXIMCO Pharmaceuticals
13.5 Boehringer Ingelheim
13.6 Chiesi Farmaceutici S.p.A.
13.7 Cipla Inc
13.8 GlaxoSmithKline,
13.9 H&T Presspart
13.10 Merck & Co Inc
13.11 Mundipharma
13.12 Novartis AG
13.13 Omron Healthcare
13.14 PARI Medical Holding
13.15 Pfizer
13.16 PNEUMA Respiratory
13.17 Roche Holding AG
13.18 Sunovion Pharmaceuticals
13.19 Teva Pharmaceutical Industries Ltd
13.20 Vectura Group

14 Appendix
14.1 Questionnaire
Note: Product cover images may vary from those shown
  • Aerocrine AB
  • AMIKO Digital Health
  • AstraZeneca
  • BEXIMCO Pharmaceuticals
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • Cipla Inc
  • GlaxoSmithKline,
  • H&T Presspart
  • Merck & Co Inc
  • Mundipharma
  • Novartis AG
  • Omron Healthcare
  • PARI Medical Holding
  • Pfizer
  • PNEUMA Respiratory
  • Roche Holding AG
  • Sunovion Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd
  • Vectura Group
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll